FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Joan Sorich

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Activities & Behaviors

Drug Evaluation

Co-author Network

Publications

TOP 3
Howard Hochster; Thomas T Chen; Janice M Lu; Day Hills; Joan Sorich; Juliet Escalon; Percy Ivy; Leonard Liebes; Franco Muggia
Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.
Sanjeev Sewak; Joan Sorich; James O'Leary
Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Deepu Mirchandani; Howard Hochster; Anne Hamilton; Leonard Liebes; Herman Yee; John P Curtin; Sang Lee; Joan Sorich; Cornelia Dellenbaugh; Franco M Muggia
Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Joan Sorich (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Howard Hochster; Thomas T Chen; Janice M Lu; Day Hills; Joan Sorich; Juliet Escalon; Percy Ivy; Leonard Liebes; Franco Muggia
Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.
Gynecologic oncology 2008;108(3):500-4.
2006: Sanjeev Sewak; Joan Sorich; James O'Leary
Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Anti-cancer drugs 2006;17(5):571-9.
2005: Deepu Mirchandani; Howard Hochster; Anne Hamilton; Leonard Liebes; Herman Yee; John P Curtin; Sang Lee; Joan Sorich; Cornelia Dellenbaugh; Franco M Muggia
Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5912-9.
2004: Joan Sorich; Beth Taubes; Allan Wagner; Howard Hochster
Oxaliplatin: practical guidelines for administration.
Clinical journal of oncology nursing 2004;8(3):251-6.
2004: Anna Pavlick; Catherine Chodkiewicz; Leonard Liebes; Anne Hamilton; Carolyn Wasserheit; Howard Hochster; James Speyer; Zoë Phillips; Andrea Downey; Joan Sorich; Franco Muggia
A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.
Anti-cancer drugs 2004;15(2):119-25.
2004: Howard Hochster; Elizabeth R Plimack; Carolyn D Runowicz; James Speyer; Robert C Wallach; Joan Sorich; John Mandeli; Scott Wadler; John Wright; Franco M Muggia
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(1):120-6.
2003: M Janice Lu; Joan Sorich; Maitreyee Hazarika; Mimi Y Kim; Giuseppe Del Priore; Allan J Jacobs; Chang Chiang; Paul C Liu; Eileen Fusco; John P Curtin; Franco M Muggia
Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy.
Hematology/oncology clinics of North America 2003;17(4):969-75.
2003: Missak Haigentz; Mimi Y Kim; Joan Sorich; Janet Lee; Howard Hochster; Manuel Macapinlac; Deepu Mirchandani; Sanjeev Sewak; Anna Pavlick; Matthew Volm; Anne Hamilton; Franco M Muggia
Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies.
Anti-cancer drugs 2003;14(4):321-6.
2003: Sanjeev Sewak; Abraham Chachoua; Anne Hamilton; Samir Taneja; Janet Lee; Minerva Utate; Joan Sorich; Franco M Muggia
A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting.
Anti-cancer drugs 2003;14(1):67-72.
2002: Franco M Muggia; Leonard Liebes; Maitreyee Hazarika; Scott Wadler; Anne Hamilton; Gila Hornreich; Joan Sorich; Chung Chiang; Elliot Newman; Milan Potmesil; Howard Hochster
Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days.
Anti-cancer drugs 2002;13(8):819-25.
2002: Elliot Newman; Stuart G Marcus; Milan Potmesil; Sanjeev Sewak; Herman Yee; Joan Sorich; Mary Hayek; Franco Muggia; Howard Hochster
Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2002;6(2):212-23; discussion 223.
2001: E Rosenberg; Rita Demopoulos; Anne Zeleniuch-Jacquotte; Herman Yee; Joan Sorich; James Speyer; Elizabeth W Newcomb
Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival.
Human pathology 2001;32(8):808-13.
2000: Franco Muggia; Leonard Liebes; Milan Potmesil; Anne Hamilton; Howard Hochster; Gila Hornreich; Joan Sorich; Andrea Downey; H Wasserstrom
Intraperitoneal topoisomerase-I inhibitors. Preliminary findings with 9-aminocamptothecin.
Annals of the New York Academy of Sciences 2000;922():178-87.
1999: Howard Hochster; Scott Wadler; Carolyn D Runowicz; Leonard Liebes; H Cohen; Robert C Wallach; Joan Sorich; Beth Taubes; James Speyer
Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2553-61.
1999: Elizabeth W Newcomb; M Sosnow; Rita Demopoulos; Anne Zeleniuch-Jacquotte; Joan Sorich; James Speyer
Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors.
The American journal of pathology 1999;154(1):119-25.
1998: T Safra; Susan Jeffers; Joan Sorich; Franco M Muggia
Gemcitabine plus cisplatin combination given with amifostine (GAP) to heavily pretreated patients with gynecologic and peritoneal cancers: tolerance and activity in ovarian cancer.
Anti-cancer drugs 1998;9(6):511-4.
1997: Howard Hochster; Leonard Liebes; James Speyer; Joan Sorich; Beth Taubes; Ruth Oratz; J Wernz; Abraham Chachoua; Ronald Blum; Anne Zeleniuch-Jacquotte
Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(8):1245-52.
1996: Carolyn Wasserheit; A Frazein; Ruth Oratz; Joan Sorich; A Downey; Howard Hochster; Abraham Chachoua; J Wernz; Anne Zeleniuch-Jacquotte; Ronald Blum; James Speyer
Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(7):1993-9.
1995: Robert J Morgan; James Speyer; James Doroshow; Kim Margolin; James Raschko; Joan Sorich; Steven Akman; Lucille Leong; George Somlo; Steven Vasilev
Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels.
Gynecologic oncology 1995;58(1):79-85.
1995: James Speyer; John Mandeli; Howard Hochster; Carolyn D Runowicz; Scott Wadler; Robert C Wallach; C Cohen; D Oette; Joan Sorich; E Demakos
A phase I trial of cyclosphosphamide and carboplatinum combined with interleukin-3 in women with advanced-stage ovarian cancer.
Gynecologic oncology 1995;56(3):387-94.
1994: Howard Hochster; Leonard Liebes; James Speyer; Joan Sorich; B Taubes; Ruth Oratz; J Wernz; Abraham Chachoua; B Raphael; R Z Vinci
Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(3):553-9.
1992: James Speyer; Joan Sorich
Intraperitoneal carboplatin: rationale and experience.
Seminars in oncology 1992;19(1 Suppl 2):107-13.
1991: U Beller; James Speyer; N Colombo; Joan Sorich; J Wernz; Howard Hochster; Anne Zeleniuch-Jacquotte; Robert F Porges; E M Beckman
Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(5):809-17.
1991: F M Muggia; K K Chan; C Russell; N Colombo; James Speyer; K Sehgal; Susan Jeffers; Joan Sorich; Lawrence Leichman; U Beller
Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2'-deoxyuridine.
Cancer chemotherapy and pharmacology 1991;28(4):241-50.
1990: James Speyer; U Beller; N Colombo; Joan Sorich; J C Wernz; Howard Hochster; M Green; Robert F Porges; F M Muggia; R Canetta
Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(8):1335-41.
1989: U Beller; Abraham Chachoua; James Speyer; Joan Sorich; M Dugan; Leonard Liebes; R Hayes; E M Beckman
Phase IB study of low-dose intraperitoneal recombinant interleukin-2 in patients with refractory advanced ovarian cancer: rationale and preliminary report.
Gynecologic oncology 1989;34(3):407-12.